---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-007127"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T08:06:46.766575+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics Q4 net loss $6.4M, revenue $1.9M; cash $57.9M; pipeline advances

## Summary
- Q4 2022 net loss $6.4M ($0.03/sh), revenue $1.9M; FY2022 net loss $26.3M ($0.15/sh), revenue $14.7M.
- Cash and securities $57.9M at Dec 31, 2022; expected to fund planned operations into Q3 2024.
- Genentech initiated Phase 2a study of RG6501 (OpRegen) for geographic atrophy; RMAT and pre-IND submitted for OPC1 and VAC2.
- Launched two new cell therapy programs for hearing/vision loss; appointed Jill Howe as CFO in 2022.

## SEC filing metadata
- accession: 0001493152-23-007127
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315223007127/0001493152-23-007127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315223007127/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-007127
- JSON: https://secwatch.observer/filing/0001493152-23-007127.json
- Plain text: https://secwatch.observer/filing/0001493152-23-007127.txt

## Key facts
- Earnings Releases
  Lineage Cell Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2022, a copy of which is furnished as Exhibit 99.1.
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000149315223007127/0001493152-23-007127-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.